We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
-14.15%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$512M
AUM Growth
-$124M
Cap. Flow
+$2.05M
Cap. Flow %
0.4%
Top 10 Hldgs %
100%
Holding
6
New
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$2.05M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 96.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$344M 67.11%
15,966,038
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$103M 20.13%
2,629,835
+40,600
+2% +$2.05M
ALKS icon
3
Alkermes
ALKS
$8.82B
$42.4M 8.29%
1,030,639
EPI icon
4
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$10.1M 1.97%
400,000
INDA icon
5
iShares MSCI India ETF
INDA
$6.71B
$9.65M 1.89%
290,000
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
$3.18M 0.62%
420,847

Similar funds

Meditor Group's Q2 2018 Portfolio in Review

As of Q2 2018, Meditor Group held 6 positions worth $512M, down 19% from $636M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2018: portfolio turnover was 0%. Meditor Group opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • Meditor Group added most to Esperion Therapeutics in Q2 2018, an estimated $2.05M increase.
  • Meditor Group's ten largest holdings make up 100% of its $512M portfolio in Q2 2018.
  • Meditor Group opened 0 new positions and closed 0 in Q2 2018.
  • Meditor Group's portfolio value fell 19% quarter-over-quarter to $512M.

Based on Meditor Group's 13F filing for Q2 2018, filed 19 Jul 2018.